Search

Displaying results 3231 - 3240 of 5451 in total
  1. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

  2. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  3. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar ...

  4. Drug

    Daunorubicin

    go.drugbank.com/drugs/DB00694
    ApprovedInvestigational

    A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

    Products: DAUNORUBICINA 20 MG/VIAL, DAUNOCIN FOR INJECTION 20 mg/vial
  5. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

    Products: Floxapen 500 mg Kapseln, FLOKSIN 500 MG FILM TABLET, 16 ADET
  6. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 Ma...

    Products: Vyndamax 61 mg Soft Capsules, VYNDAQEL® 20 MG CAPSULABLANDA.
  7. Drug

    Cloxacillin

    go.drugbank.com/drugs/DB01147
    ApprovedInvestigationalVet approved

    A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.

    Products: CLOXACAP 250 CAPSULE 250 mg, CLOXACAP 500 CAPSULE 500 mg
  8. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients.

  9. Drug

    Masoprocol

    go.drugbank.com/drugs/DB00179
    Investigational

    It also serves as an antioxidant in fats and oils. [PubChem]

  10. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.